CONJUGATE VACCINE MARKET ANALYSIS

Conjugate Vaccine Market, by Product Types (Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine), by Disease Indication (Pneumococcal, Influenza, Meningococcal, and Typhoid), by Pathogen Type (Bacterial and Viral), by Patient Type (Pediatric and Adults), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.

Market Dynamics

Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2017, 11.9 – 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.

Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.

This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.

Key features of the study:

  • This report provides in-depth analysis of the global conjugate vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2018–2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global conjugate vaccine market based on the following parameters – company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global conjugate vaccine market, research and consulting firms, new entrants, and financial analysts

Request the sample copy here:

https://www.coherentmarketinsights.com/insight/request-sample/2697

Request the pdf brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2697

Detailed Segmentation:

  • Global Conjugate vaccine market, By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
  • Global Conjugate vaccine market, By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
  • Global Conjugate vaccine market, By Pathogen Type:
    • Bacterial
    • Viral
  • Global Conjugate vaccine market, By Patients Type:
    • Pediatric
    • Adults
  • Global Conjugate vaccine market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type:
        • Pediatric
        • Adults
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type:
        • Pediatric
        • Adults
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
  • Company Profiles
    • Sanofi S.A *

·

o

      • Company Overview
      • Technology Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech.
    • Serum institute of India Pvt. Ltd.
    • Biological E. Limited
    • Bio-Med

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2697

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

  • Customized market research service
  • Industry analysis services
  • Business consulting services
  • Market intelligence services
  • Long term engagement model
  • Country specific analysis

Explore cmi services here

Contact Us:

Mr. shah

Coherent Market Insights Pvt. Ltd.

Address:  Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email:  sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/market-insight/conjugate-vaccine-market-2697